Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of mesenchymal stem cell exosome in preparation of osteoporosis prevention and treatment drug

An osteoporosis, stem cell technology, applied in the field of stem cell applications, can solve problems such as adverse reactions and mandibular osteonecrosis

Pending Publication Date: 2018-09-04
XIANGYA HOSPITAL CENT SOUTH UNIV
View PDF6 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Bisphosphonates lead the current OP market, but long-term use can lead to serious adverse reactions, such as atypical fractures and osteonecrosis of the jaw
But so far, there is no research report on the prevention and treatment of OP directly using exosomes derived from human umbilical cord MSCs at home and abroad.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of mesenchymal stem cell exosome in preparation of osteoporosis prevention and treatment drug
  • Application of mesenchymal stem cell exosome in preparation of osteoporosis prevention and treatment drug
  • Application of mesenchymal stem cell exosome in preparation of osteoporosis prevention and treatment drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Isolation and culture of human umbilical cord MSCs exosomes:

[0048] (1) Isolation and culture of human umbilical cord MSCs

[0049] Human umbilical cord MSCs were isolated from the umbilical cord 10-15em near the fetal end of healthy full-term newborns, and cultured in DMEM-F12 complete medium containing 10% fetal bovine serum, 100U / mL penicillin and 100mg / L streptomycin, using tissue block paste Human umbilical cord mesenchymal stem cells were isolated by the wall method, and were cultured in primary culture and subculture. The morphology of obtained human umbilical cord MSCs is as follows: figure 1 As shown, it is in the shape of a flat long shuttle.

[0050] (2) Extraction of human umbilical cord MSCs exosomes

[0051] The P3-P6 generation human umbilical cord MSCs were inoculated in culture flasks, and when they were fused to 70%-80%, the cells were washed with PBS and replaced with fresh exosome-free MSCs containing 10% fetal bovine serum, 100 U / mL penicillin ...

Embodiment 2

[0056] Effect of human umbilical cord MSCs exosomes on postmenopausal OP model:

[0057] (1) Mouse model:

[0058] Two-month-old female SPF grade C57BL / 6 mice were selected. The postmenopausal OP model was constructed by performing bilateral ovariectomy (OVX) on 2-month-old female mice, and a sham operation (Sham) group was established at the same time. Experimental mice were purchased from Hunan Slack Jingda Animal Experiment Co., Ltd.

[0059] (2) Group experiment:

[0060] After 1 week of OVX, the mice were equally divided into OVX control group (OVX group) and OVX+human umbilical cord MSCs exosome intervention group (OVX+MSCs-Exo group). 100 μg human umbilical cord mesenchymal stem cell exosomes (MSCs-Exo (dissolved in 100 μL PBS)) or 100 μL PBS were injected once a week through the tail vein for 2 consecutive months. Sham group was also given equal volume of PBS at the same time point.

[0061] The mice were anesthetized and sacrificed at the corresponding time point...

Embodiment 3

[0063] Effects of human umbilical cord MSCs exosomes on disuse OP model:

[0064] (1) Mouse model:

[0065] Three-month-old female SPF grade C57BL / 6 mice were selected. 3-month-old female mice were subjected to tail suspension (tailsuspension; TS) to reduce the load on their hind limbs, and a disuse OP model was constructed, while the control group moved freely. Experimental mice were purchased from Hunan Slack Jingda Animal Experiment Co., Ltd.

[0066] (2) Group experiment:

[0067] 3-month-old female SPF grade C57BL / 6 mice were randomly divided into non-suspended control group (Control group), tail-suspended group (TS group) and tail-suspended + human umbilical cord MSCs exosome intervention group (TS+MSCs-Exo Group). The TS+MSCs-Exo group was injected with 100 μg MSCs-Exo (dissolved in 100 μL PBS) twice a week, and the Control group and TS group were injected with 100 μL PBS once a week for 3 consecutive weeks.

[0068] The mice were anesthetized and sacrificed at the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses an application of a mesenchymal stem cell exosome in the preparation of an osteoporosis prevention and treatment drug. The extracted human umbilical cord mesenchymal stem cellexosome is intravenously injected to improve the bone volume fraction of distal femur cancellous bones, enhance the trabecular thickness and enhance the trabecular number in order to achieve the purpose of treating osteoporosis. A new way is provided for the safe and effective treatment of osteoporosis. The extracted exosome is obtained by centrifugation, concentration and reagent extraction, anda preparation method of the exosome is simple and efficient, and can effectively maintain the activity of the exosome.

Description

technical field [0001] The present invention relates to the technical field of stem cell application, in particular, to the application of exosomes of mesenchymal stem cells in the preparation of drugs, food or health products for the prevention and treatment of osteoporosis, especially to a kind of human umbilical cord mesenchymal stem cells Application of exosomes in the preparation of medicines, food or health products for preventing and treating osteoporosis. Background technique [0002] Osteoporosis (OP) is a metabolic bone disease characterized by decreased bone mass and destruction of bone microarchitecture, leading to increased bone fragility and susceptibility to fracture. OP is divided into two categories: primary and secondary. Primary OP is further divided into postmenopausal OP, senile OP, and idiopathic OP. Secondary OP is mostly caused by diseases or other factors, including obsolete OP. Practicality OP et al. According to statistics from the International ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/51A61K35/28A61P19/10A23L33/00
CPCA61P19/10A23L33/00A61K35/28A61K35/51A23V2002/00A23V2200/306
Inventor 谢辉胡阴张燕陈春媛饶珊珊谭艺娟罗娟黄杰殷豪王振兴曹加刘祎伟
Owner XIANGYA HOSPITAL CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com